卵巣癌の予後予測マーカーとしての組織経路インヒビター2 の有用性についての検討

Abstract

Abstract. Tissue factor pathway inhibitor‑2 (TFPI2) is a tumor marker for diagnosing ovarian cancer and ovarian clear cell carcinoma (OCCC); however, its effectiveness as a prognostic marker remains unclear. The present study aimed to investigate the utility of TFPI2 as a prognostic marker for ovarian cancer. A total of 256 cases of ovarian cancer was collected at Nara Medical University (Kashihara, Japan) from January 2008 to January 2022. The majority of cases were serous carcinoma (109, 42.6%), followed by OCCC (66, 25.8%), mucinous carcinoma (40, 15.6%), endometrial carcinoma (15, 5.9%), and other (26, 10.2%). The median preoperative serum TFPI2 for ovarian cancer was 219.0 (82.5‑5,824.2) pg/ml. Overall survival (OS) of patients with non‑OCCC and OCCC was calculated using the cut‑off value determined obtained through receiver operating characteristic curve analysis. Cut‑off values of TFPI2 for OS were 201 for non‑OCCC and 255 pg/ml for OCCC. In univariate analysis, OS was significantly elevated in patients with non‑OCCC and OCCC who had TFPI2 levels ≥201 pg/ml (P<0.001) and ≥255 pg/ml (P=0.036), respectively. Progression‑free survival (PFS) was significantly elevated in patients with non‑OCCC and OCCC who had TFPI2 levels ≥201 and ≥255 pg/ml (both P<0.001), respectively. Multivariate analysis revealed that OS was significantly higher in patients with non‑OCCC who had TFPI2 levels ≥201 pg/ml (P=0.021), while PFS was significantly higher in patients with OCCC who had TFPI2 levels ≥255 pg/ml (P=0.020). These findings suggest that TFPI2 is a potential prognostic marker for ovarian carcinoma.権利情報：© Maehana et al. This is an open access article distributed under the terms of Creative Commons Attribution License